Zacks’ analyst wrote, “United Therapeutics reported fourth-quarter earnings of $1.60 per share, well above the year-ago earnings of $0.77 and the Zacks Consensus Estimate of $1.25. Higher revenues led to the year-over-year improvement in earnings. Fourth quarter revenues increased 24.9% to $243.8 million, well above the Zacks Consensus Estimate of $232 million. Although we believe United Therapeutics’ existing PAH product portfolio will drive strong top-and bottom-line growth, we remain concerned about the generic challenge being faced by Remodulin. We expect investor focus to remain on the FDA’s response to the UT-15C re-submission. We maintain our Neutral recommendation on the stock. “
A number of other analysts have also recently weighed in on UTHR. Analysts at Jefferies Group raised their price target on shares of United Therapeutics from $45.00 to $52.00 in a research note to investors on Wednesday, February 27th. They now have a hold rating on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of United Therapeutics from $44.00 to $54.00 in a research note to investors on Wednesday, February 27th. They now have a hold rating on the stock. Finally, analysts at Deutsche Bank reiterated a hold rating on shares of United Therapeutics in a research note to investors on Wednesday, February 27th. They now have a $56.00 price target on the stock, up previously from $52.00.
Five research analysts have rated the stock with a buy rating, nine have assigned a hold rating, and two have assigned a sell rating to the company. The stock currently has a consensus rating of hold and a consensus target price of $54.71.
Shares of United Therapeutics (NASDAQ: UTHR) traded down 0.06% during mid-day trading on Wednesday, hitting $61.86. United Therapeutics has a 52 week low of $40.34 and a 52 week high of $62.82. The stock’s 50-day moving average is currently $57.04. The company has a market cap of $3.104 billion and a P/E ratio of 10.84.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.